



For internal use

About Jiksak Bioengineering



Name	Jiksak Bioengineering Inc.
Established	Feb. 7 th , 2017
Founder	Jiro Kawada, PhD
Capital Stock	10 M yen (Cumulative Funds :1 B yen)
Head Office	322, CIBERNICS MEDICAL INNOVATION BASE-A, Tonomachi 3-25-16, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-0821, JAPAN
Staff	Board Members: 3 persons, Employee: 8 persons
Shareholders	ANRI, Cyberdyne Inc., CEJ Capital, Zeon corp. etc

Collaborator
Prof. Shinsuke Shibata
(Niigata University Graduate School of Medical and Dental Sciences)
(Keio University School of Medicine)

Scientific advisor
Prof. Yoshiho Ikeuchi
(Institute of Industrial Science, The University of Tokyo)
Prof. Haruhiko Kamada
(National Institutes of Biomedical Innovation, Health and Nutrition)
Prof. Yukihide Tomari
(Laboratory of RNA Function, Institute for Quantitative Biosciences, The University of Tokyo)

Business①
Nerve Allograft

Business②
Drug Discovery/Delivery

Core Technology

Engineered Human Synapse

NerveOrganoid™



Neuron-selective Drug Delivery







Overview Jiksak Drug Delivery System (DDS)

Jiksak shuttle technology capabilities

- **Neuron-selective Drug Delivery through intravenous injection.**
- Jiksak shuttle's selectivity increases drug concentration in neurons and reduces drug off-targeting to cells leading to adverse reaction reduction
- Versatility to deliver various types of molecules to neurons.

Collaboration Opportunity

- Seeking potential molecules for neuron targeting delivery





Jiksak's Innovation, Neuron Selective Drug Delivery System

1. Neuron-selective.
2. Small molecules, oligonucleotides and biologics delivery to motor axons and cell bodies (and other neurons).
3. Administered by systemic injection (IV).

